Agenus Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2016. Agenus is an immuno-oncology company developing antibody platforms and candidates, cancer vaccines, and vaccine adjuvants. Its candidates remain largely in development, and the company has incurred substantial losses since inception.
Financial results and position
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $6.6 million | $6.4 million | $12.6 million | $10.3 million |
| Research and development expense | $22.4 million | $24.8 million | $47.4 million | $34.0 million |
| General and administrative expense | $7.1 million | $8.0 million | $16.3 million | $13.5 million |
| Operating loss | $23.6 million | $33.2 million | $51.6 million | $51.5 million |
| Net loss attributable to common stockholders | $28.4 million | $40.5 million | $60.2 million | $59.3 million |
| Loss per common share | $0.33 | $0.53 | $0.69 | $0.83 |
| Cash used in operating activities | Not stated separately | Not stated separately | $40.0 million | $9.6 million |
- Revenue was primarily collaboration and license-related, including Incyte development-cost reimbursements. Six-month revenue increased 22%, including higher Incyte reimbursements; Q2 revenue increased modestly.
- Q2 R&D expense fell 10%, partly because Q2 2015 included a one-time $13.2 million in-process research and development charge. Six-month R&D rose 39%, reflecting antibody-program services, increased headcount, manufacturing-facility costs, and share-based compensation.
- Six-month net loss was broadly similar to 2015, while Q2 net loss narrowed. Comparisons were affected by lower contingent-purchase-price fair-value charges and non-operating expense than in 2015, partly offset by substantially higher interest expense.
- Gross profit and gross margin are not separately presented; a meaningful operating margin is not provided.
Liquidity, debt, and capital
- At June 30, 2016, cash and cash equivalents were $73.4 million and short-term investments were $49.9 million, totaling $123.3 million, down $48.4 million from year-end 2015.
- Current assets were $136.1 million and current liabilities were $33.1 million. The company reported an accumulated deficit of $838.4 million and stockholders’ equity of $16.9 million.
- Debt principal, including accrued interest, was reported as $125.7 million; the balance-sheet carrying amount was $122.3 million. The debt includes $100 million of royalty-backed notes bearing 13.5% annual interest, compounded quarterly, and $14 million of 2015 subordinated notes due February 2018 bearing 8% interest. Six-month net interest expense was $8.3 million.
- Management said current cash, cash equivalents, and short-term investments were expected to fund operations through the first half of 2017, based on current plans. It expects to seek additional funding before resources are depleted; the filing warns financing may not be available on favorable terms or at all.
- At June 30, $70.3 million remained under the shelf registration statement, and 10 million shares were available under the at-the-market sales agreement. The company increased authorized common shares from 140 million to 240 million in June.
Outlook, developments, and principal risks
- Management expects significant losses over the next several years and says long-term liquidity depends on added capital, partnerships or licensing, and eventual development and commercialization outcomes. It may discontinue infeasible programs, limit capital spending, or reduce operations.
- In 2016, anti-GITR and anti-CTLA-4 candidates began Phase 1 trials. Management targeted a randomized Prophage trial for newly diagnosed glioblastoma in the second half of 2016, and an initial AutoSynVax clinical trial within the following nine months. These were plans, not assured milestones.
- Agenus said GSK planned to file for approval of its shingles vaccine candidate in the second half of 2016; QS-21-containing product launches were anticipated in 2018, subject to regulatory approval and other conditions. Royalties from GSK’s shingles and malaria vaccines are pledged to service the royalty-backed notes. Janssen terminated its QS-21 license in May 2016.
- Key risks include clinical, regulatory, manufacturing, enrollment, and commercialization uncertainty; dependence on collaborators, particularly Incyte and GSK; the need to fund 50% of costs for certain Incyte programs; and the possibility of additional financing needs or insolvency if losses continue and capital cannot be raised.
- The royalty-backed notes create material potential obligations: purchasers may require repurchase of up to 15% of notes in September 2018, and the agreement includes make-whole and accelerated-payment provisions. Agenus guarantees specified payments. Failure of GSK products to win approval or generate royalties could affect debt servicing and liquidity.
- Other disclosed risks include competition and intellectual-property challenges, reliance on third-party manufacturing, and operational disruption. The company was transferring German operations to Switzerland and the UK, with completion expected in Q3 2016. Management reported disclosure controls were effective and no material second-quarter change in internal control over financial reporting.
Important facts for investors to verify
- Whether the $123.3 million liquidity balance and stated runway through the first half of 2017 remain adequate given the $40.0 million six-month operating cash outflow.
- Debt terms and actual royalty flows under the 13.5% royalty-backed notes, including any put, make-whole, or default-payment exposure.
- Progress and funding requirements for Incyte cost-sharing programs, planned clinical trials, and the GSK shingles vaccine filing and launch timetable.
- Availability and potential dilution from the shelf registration, at-the-market program, stock-based awards, warrants, and other potential share issuances.
- Whether program timelines, trial enrollment, manufacturing capacity, and partnership assumptions support management’s liquidity and development plans.